{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:57:35Z","timestamp":1790765855894,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Radioactive iodine therapy requires individualized decisions regarding patient selection, administered activity planning, imaging assessment, and follow-up. This systematic review summarizes current applications of artificial intelligence (AI) in the\n                    <jats:sup>131<\/jats:sup>\n                    I treatment pathway and evaluates barriers limiting clinical implementation. Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and Wiley databases were searched for original studies involving human patients treated with\n                    <jats:sup>131<\/jats:sup>\n                    I for differentiated thyroid cancer or benign thyroid disease, where AI, deep learning (DL), or machine learning (ML) methods were utilized. Evidence was synthesized, and study quality was assessed using the NIH\/NHLBI Study Quality Assessment Tool. Among 775 identified records, 24 studies met inclusion criteria. AI applications included pretreatment decision support, detection and characterization of iodine-avid disease, dosimetry and activity optimization, radiation-safety assessment, treatment response prediction, levothyroxine dose estimation, and recurrence-risk stratification. The available evidence was dominated by retrospective, single-center studies, primarily focused on differentiated thyroid cancer, with limited external validation. AI has the potential to improve standardization and personalization of\n                    <jats:sup>131<\/jats:sup>\n                    I therapy, but heterogeneous methodologies and insufficient evidence of clinical utility currently restrict routine adoption. Prospective multicenter studies with harmonized endpoints and robust validation are required to facilitate clinical translation.\n                  <\/jats:p>","DOI":"10.1007\/s13139-026-01049-w","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:42:46Z","timestamp":1783734166000},"page":"490-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From Patient Selection to Surveillance: Artificial Intelligence Applications in Radioiodine Therapy \u2013 A Systematic Review"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1581-2154","authenticated-orcid":false,"given":"Maria","family":"Obrycka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Abdelrazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-0369","authenticated-orcid":false,"given":"\u0141ukasz","family":"\u017bukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-6585","authenticated-orcid":false,"given":"Janusz","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6583","authenticated-orcid":false,"given":"Piotr","family":"Szumowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1210\/er.2012-1030","volume":"33","author":"SJ Bonnema","year":"2012","unstructured":"Bonnema SJ, Heged\u00fcs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920\u201380.","journal-title":"Endocr Rev"},{"key":"1049_CR2","first-page":"1188","volume":"43","author":"JK Chung","year":"2002","unstructured":"Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188\u2013200.","journal-title":"J Nucl Med"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00259-016-3548-5","volume":"44","author":"VR McCready","year":"2017","unstructured":"McCready VR. Radioiodine - the success story of nuclear medicine: 75th Anniversary of the first use of iodine-131 in humans. Eur J Nucl Med Mol Imaging. 2017;44:179\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","volume":"109","author":"S Aghevlian","year":"2017","unstructured":"Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102\u201318.","journal-title":"Adv Drug Deliv Rev"},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/pharmaceutics15061733","volume":"15","author":"N Lepareur","year":"2023","unstructured":"Lepareur N, Ram\u00e9e B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted radionuclide therapy. Pharmaceutics. 2023;15:1733.","journal-title":"Pharmaceutics"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","volume":"131","author":"S Hertz","year":"1946","unstructured":"Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81\u20136.","journal-title":"J Am Med Assoc"},{"key":"1049_CR7","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180136","volume":"91","author":"PS Choudhury","year":"2018","unstructured":"Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018;91:20180136.","journal-title":"Br J Radiol"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00259-010-1398-0","volume":"37","author":"M Salvatori","year":"2010","unstructured":"Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:821\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fendo.2017.00312","volume":"8","author":"D Tumino","year":"2017","unstructured":"Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017;8:312.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/j.semnuclmed.2024.05.002","volume":"54","author":"NC Nguyen","year":"2024","unstructured":"Nguyen NC, Anigati EM, Desai NB, \u00d6z OK. Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies. Semin Nucl Med. 2024;54:488\u201396.","journal-title":"Semin Nucl Med"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5603\/EP.a2023.0028","volume":"74","author":"W Wu","year":"2023","unstructured":"Wu W, Li S, Xu K, Meng Z. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study. Endokrynol Pol. 2023;74:260\u201370.","journal-title":"Endokrynol Pol"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0140-6736(92)92421-B","volume":"340","author":"P Hall","year":"1992","unstructured":"Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1\u20134.","journal-title":"Lancet"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1089\/thy.2014.0557","volume":"25","author":"GH Seo","year":"2015","unstructured":"Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid. 2015;25:927\u201334.","journal-title":"Thyroid"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1007\/s00259-022-05779-9","volume":"49","author":"S Kim","year":"2022","unstructured":"Kim S, Bang JI, Boo D, et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging. 2022;49:3547\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1097\/JS9.0000000000002813","volume":"111","author":"H Su","year":"2025","unstructured":"Su H, Yang F, Wang Z, et al. Meta-analysis of secondary hematologic malignancy risks following radioactive iodine therapy for differentiated thyroid cancer. Int J Surg. 2025;111:7312\u201321.","journal-title":"Int J Surg"},{"key":"1049_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25072","volume":"4","author":"SR Shim","year":"2021","unstructured":"Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ. Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2125072.","journal-title":"JAMA Netw Open"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","volume":"40","author":"E Pasqual","year":"2022","unstructured":"Pasqual E, Schonfeld S, Morton LM, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J Clin Oncol. 2022;40:1439\u201349.","journal-title":"J Clin Oncol"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1002\/1878-0261.70078","volume":"19","author":"J Kim","year":"2025","unstructured":"Kim J, Bae S, Choi J, et al. Association of high-dose radioactive iodine therapy with PPM1D-mutated clonal hematopoiesis in older individuals. Mol Oncol. 2025;19:3079\u201395.","journal-title":"Mol Oncol"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.2016.67.7419","volume":"34","author":"L Furuya-Kanamori","year":"2016","unstructured":"Furuya-Kanamori L, Bell KJ, Clark J, et al. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34:3672\u20139.","journal-title":"J Clin Oncol"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ctrv.2015.09.001","volume":"41","author":"SC Clement","year":"2015","unstructured":"Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma\u2014a systematic review. Cancer Treat Rev. 2015;41:925\u201334.","journal-title":"Cancer Treat Rev"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13193-021-01429-y","volume":"13","author":"JB Shank","year":"2022","unstructured":"Shank JB, Are C, Wenos CD. Thyroid cancer: global burden and trends. Indian J Surg Oncol. 2022;13:40\u20135.","journal-title":"Indian J Surg Oncol"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783\u201395.","journal-title":"Lancet"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1088\/0031-9155\/56\/22\/020","volume":"56","author":"S Lamart","year":"2011","unstructured":"Lamart S, Bouville A, Simon SL, et al. Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on 131I in the thyroid. Phys Med Biol. 2011;56:7317\u201338.","journal-title":"Phys Med Biol"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841\u2013985.","journal-title":"Thyroid"},{"key":"1049_CR25","unstructured":"Haddad RI, Bischoff L, Applewhite M, et al. NCCN guidelines insights: thyroid carcinoma, version 1.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2025;23:e250033."},{"key":"1049_CR26","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram AM, Giovanella L, Greenspan B, et al. SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med. 2022;63:15N-35N.","journal-title":"J Nucl Med"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1007\/s00259-023-06274-5","volume":"50","author":"A Campenn\u00ec","year":"2023","unstructured":"Campenn\u00ec A, Avram AM, Verburg FA, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023;50:3324\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3803\/EnM.2025.2464","volume":"40","author":"KJ Kim","year":"2025","unstructured":"Kim KJ, Song EY, Kim MJ, et al. 2025 Korean Thyroid Association management guidelines for radioactive iodine therapy in patients with hyperthyroidism. Endocrinol Metab (Seoul). 2025;40:342\u201356.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1049_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000530463","volume":"101","author":"YM Ali Hailan","year":"2023","unstructured":"Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101:362\u20138.","journal-title":"Oncology"},{"key":"1049_CR30","unstructured":"Frane N, Bitterman A. Radiation safety and protection. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557499\/. Accessed 18 Jan 2026."},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/thy.2012.0136","volume":"23","author":"SY Sohn","year":"2013","unstructured":"Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2013;23:741\u20137.","journal-title":"Thyroid"},{"key":"1049_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4158\/EP13504.RA","volume":"20","author":"L Kessler","year":"2014","unstructured":"Kessler L, Palla J, Baru JS, et al. Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract. 2014;20:737\u201345.","journal-title":"Endocr Pract"},{"key":"1049_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1089\/thy.2019.0180","volume":"29","author":"F Azizi","year":"2019","unstructured":"Azizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial. Thyroid. 2019;29:1192\u2013200.","journal-title":"Thyroid"},{"key":"1049_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-0038-1629854","volume":"37","author":"CH Kao","year":"1998","unstructured":"Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin. 1998;37:23\u20135.","journal-title":"Nuklearmedizin"},{"key":"1049_CR35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.31557\/APJCP.2018.19.11.3137","volume":"19","author":"N Ahmed","year":"2018","unstructured":"Ahmed N, Niyaz K, Borakati A, et al. Hybrid SPECT\/CT imaging in the management of differentiated thyroid carcinoma. Asian Pac J Cancer Prev. 2018;19:303\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1049_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089552","volume":"14","author":"D Oh","year":"2024","unstructured":"Oh D, Ryoo HG, Chung HW, et al. Artificial intelligence-based CT-free quantitative thyroid SPECT for thyrotoxicosis: study protocol of a multicentre, prospective, non-inferiority study. BMJ Open. 2024;14:e089552.","journal-title":"BMJ Open"},{"key":"1049_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40658-023-00536-9","volume":"10","author":"K Kwon","year":"2023","unstructured":"Kwon K, Hwang D, Oh D, et al. CT-free quantitative SPECT for automatic evaluation of %thyroid uptake based on deep-learning. EJNMMI Phys. 2023;10:20.","journal-title":"EJNMMI Phys"},{"key":"1049_CR38","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, et al. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;22:e136\u201372.","journal-title":"Lancet Oncol"},{"key":"1049_CR39","unstructured":"Blum M. Ultrasonography of the thyroid. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/. Accessed 18 Jan 2026."},{"key":"1049_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41568-018-0016-5","volume":"18","author":"A Hosny","year":"2018","unstructured":"Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18:500\u201310.","journal-title":"Nat Rev Cancer"},{"key":"1049_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/ct.2023;35.57-60","volume":"35","author":"OE Kawkgi","year":"2023","unstructured":"Kawkgi OE. Predictors of poor response to radioactive iodine treatment in Graves\u2019 disease. Clin Thyroidol. 2023;35:57\u201360.","journal-title":"Clin Thyroidol"},{"key":"1049_CR42","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2022.0225.r1.19102022","volume":"141","author":"IK Bolakale-Rufai","year":"2023","unstructured":"Bolakale-Rufai IK, Abioro I, Ngene SO, Woldeamanuel Y. Efficacy of methimazole before the administration of radioactive iodine in the management of Graves\u2019 disease: a systematic review and meta-analysis. Sao Paulo Med J. 2023;141:e2022225.","journal-title":"Sao Paulo Med J"},{"key":"1049_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1089\/thy.2013.0238","volume":"24","author":"SY Sohn","year":"2014","unstructured":"Sohn SY, Choi JH, Kim NK, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Thyroid. 2014;24:872\u20137.","journal-title":"Thyroid"},{"key":"1049_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101013","volume":"72","author":"H Shen","year":"2024","unstructured":"Shen H, Zhu R, Liu Y, et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist Updat. 2024;72:101013.","journal-title":"Drug Resist Updat"},{"key":"1049_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoto.2021.0288","volume":"147","author":"DL James","year":"2021","unstructured":"James DL, Ryan \u00c9J, Davey MG, et al. Radioiodine remnant ablation for differentiated thyroid cancer: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147:544\u201352.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1049_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.amjsurg.2021.03.068","volume":"223","author":"M Shalaby","year":"2022","unstructured":"Shalaby M, Hadedeya D, Toraih EA, et al. Predictive factors of radioiodine therapy failure in Graves\u2019 disease: a meta-analysis. Am J Surg. 2022;223:287\u201396.","journal-title":"Am J Surg"},{"key":"1049_CR47","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab. 2002;87:1073\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1049_CR48","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/MNM.0000000000002033","volume":"46","author":"MN Acar Tayyar","year":"2025","unstructured":"Acar Tayyar MN, Uyanik E, M\u00fclazimo\u011flu M, et al. Graves\u2019 disease: is hyperthyroidism still present 6 months after radioactive iodine treatment really a failure? Nucl Med Commun. 2025;46:1037\u201342.","journal-title":"Nucl Med Commun"},{"key":"1049_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2023.103046","volume":"92","author":"S Dayarathna","year":"2024","unstructured":"Dayarathna S, Islam KT, Uribe S, et al. Deep learning based synthesis of MRI, CT and PET: review and analysis. Med Image Anal. 2024;92:103046.","journal-title":"Med Image Anal"},{"key":"1049_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2023.102762","volume":"85","author":"J Li","year":"2023","unstructured":"Li J, Chen J, Tang Y, et al. Transforming medical imaging with Transformers? A comparative review of key properties, current progresses, and future perspectives. Med Image Anal. 2023;85:102762.","journal-title":"Med Image Anal"},{"key":"1049_CR51","first-page":"188","volume":"8","author":"D Sihombing","year":"2025","unstructured":"Sihombing D. Comparison of algorithm performance, random forest regression, SVR, and gradient boosting in predicting academic grades based on student lifestyle. J Intell Decis Support Syst. 2025;8:188\u201397.","journal-title":"J Intell Decis Support Syst"},{"key":"1049_CR52","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.3390\/jcm13237337","volume":"13","author":"A Lastrucci","year":"2024","unstructured":"Lastrucci A, Wandael Y, Barra A, et al. Revolutionizing radiology with natural language processing and chatbot technologies: a narrative umbrella review on current trends and future directions. J Clin Med. 2024;13:7337.","journal-title":"J Clin Med"},{"key":"1049_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedinformatics5040067","volume":"5","author":"T Abbasi","year":"2025","unstructured":"Abbasi T, Pinky L. Personalized prediction in nephrology: a comprehensive review of artificial intelligence models using biomarker data. BioMedInformatics. 2025;5:67.","journal-title":"BioMedInformatics"},{"key":"1049_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.csbj.2025.12.033","volume":"31","author":"B Ahmad","year":"2026","unstructured":"Ahmad B, Ouahada K, Hamam H. Machine learning for drug-target interaction prediction: a comprehensive review of models, challenges, and computational strategies. Comput Struct Biotechnol J. 2026;31:316\u201345.","journal-title":"Comput Struct Biotechnol J"},{"key":"1049_CR55","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.3390\/cancers15194674","volume":"15","author":"P Msaouel","year":"2023","unstructured":"Msaouel P, Lee J, Thall PF. Interpreting randomized controlled trials. Cancers (Basel). 2023;15:4674.","journal-title":"Cancers (Basel)"},{"key":"1049_CR56","volume-title":"Artificial intelligence in health care: the hope, the hype, the promise, the peril","author":"National Academy of Medicine","year":"2023","unstructured":"National Academy of Medicine. Artificial intelligence in health care: the hope, the hype, the promise, the peril. Washington (DC): National Academies Press; 2023."},{"key":"1049_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrai.2025.100030","volume":"3","author":"B Kocak","year":"2025","unstructured":"Kocak B, Klontzas ME, Stanzione A, et al. Evaluation metrics in medical imaging AI: fundamentals, pitfalls, misapplications, and recommendations. Eur J Radiol Artif Intell. 2025;3:100030.","journal-title":"Eur J Radiol Artif Intell"},{"key":"1049_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jbi.2017.10.008","volume":"76","author":"CG Walsh","year":"2017","unstructured":"Walsh CG, Sharman K, Hripcsak G. Beyond discrimination: a comparison of calibration methods and clinical usefulness of predictive models of readmission risk. J Biomed Inform. 2017;76:9\u201318.","journal-title":"J Biomed Inform"},{"key":"1049_CR59","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.3390\/healthcare13243208","volume":"13","author":"S Lopes","year":"2025","unstructured":"Lopes S, Mascarenhas M, Fonseca J, Fernandes MGO, Leite-Moreira AF. Unveiling the algorithm: the role of explainable artificial intelligence in modern surgery. Healthcare (Basel). 2025;13:3208.","journal-title":"Healthcare (Basel)"},{"key":"1049_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100686","volume":"38","author":"MG Hanna","year":"2025","unstructured":"Hanna MG, Pantanowitz L, Jackson B, et al. Ethical and bias considerations in artificial intelligence\/machine learning. Mod Pathol. 2025;38:100686.","journal-title":"Mod Pathol"},{"key":"1049_CR61","unstructured":"PRISMA. PRISMA 2020 flow diagram. https:\/\/www.prisma-statement.org\/prisma-2020-flow-diagram. Accessed 18 Jan 2026."},{"key":"1049_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1049_CR63","doi-asserted-by":"publisher","first-page":"1685088","DOI":"10.3389\/fmedt.2025.1685088","volume":"7","author":"Y Su","year":"2025","unstructured":"Su Y, Cai Y, Jin S, et al. Explainable multi-modal machine learning for predicting occult pulmonary metastases in differentiated thyroid cancer: a SHAP-based approach prior to radioactive iodine scans. Front Med Technol. 2025;7:1685088.","journal-title":"Front Med Technol"},{"key":"1049_CR64","doi-asserted-by":"publisher","first-page":"1429115","DOI":"10.3389\/fendo.2024.1429115","volume":"15","author":"X Gao","year":"2024","unstructured":"Gao X, Chen H, Wang Y, et al. Automatic prediction of non-iodine-avid status in lung metastases for radioactive I131 treatment in differentiated thyroid cancer patients. Front Endocrinol (Lausanne). 2024;15:1429115.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1697233","volume":"16","author":"H Song","year":"2025","unstructured":"Song H, Fei M, Tao H, et al. Prediction of 131I uptake in lung metastases of differentiated thyroid cancer using deep learning. Front Endocrinol (Lausanne). 2025;16:1697233.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/jcm13010117","volume":"13","author":"MF Georgiou","year":"2024","unstructured":"Georgiou MF, Nielsen JA, Chiriboga R, Kuker RA. An artificial intelligence system for optimizing radioactive iodine therapy dosimetry. J Clin Med. 2024;13:117.","journal-title":"J Clin Med"},{"key":"1049_CR67","doi-asserted-by":"publisher","first-page":"24381","DOI":"10.1038\/s41598-025-09212-7","volume":"15","author":"M Jalilifar","year":"2025","unstructured":"Jalilifar M, Sadeghi M, Emami-Ardekani A, et al. AI-enhanced patient-specific dosimetry in I-131 planar imaging with a single oblique view. Sci Rep. 2025;15:24381.","journal-title":"Sci Rep"},{"key":"1049_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40658-024-00623-5","volume":"11","author":"D Ciucci","year":"2024","unstructured":"Ciucci D, Cassano B, Donatiello S, et al. Fit of biokinetic data in molecular radiotherapy: a machine learning approach. EJNMMI Phys. 2024;11:19.","journal-title":"EJNMMI Phys"},{"key":"1049_CR69","first-page":"2621","volume":"26","author":"M Popovic","year":"2021","unstructured":"Popovic M, Sobic Saranovic DS, Nikoli\u0107 M, et al. Radioactive iodine treatment planning for differentiated thyroid carcinoma: comparison of different machine learning classification models. J BUON. 2021;26:2621\u20138.","journal-title":"J BUON"},{"key":"1049_CR70","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1088\/1361-6498\/aa9b9b","volume":"38","author":"M Ebrahimi","year":"2018","unstructured":"Ebrahimi M, Kardan M, Changizi V, Pooya S, Geramifar P. Prediction of dose to the relatives of patients treated with radioiodine-131 using neural networks. J Radiol Prot. 2018;38:422\u201333.","journal-title":"J Radiol Prot"},{"key":"1049_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2025.1599657","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang C, Zhang D, Tang L, Tian F. Research on a machine learning method for predicting discharge time of thyroid cancer patients receiving 131I treatment: a retrospective study. Front Physiol. 2025;16:1599657.","journal-title":"Front Physiol"},{"key":"1049_CR72","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1002\/mp.15196","volume":"48","author":"Q Lin","year":"2021","unstructured":"Lin Q, Cao C, Li T, et al. Multiclass classification of whole-body scintigraphic images using a self-defined convolutional neural network with attention modules. Med Phys. 2021;48:5782\u201393.","journal-title":"Med Phys"},{"key":"1049_CR73","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1038\/s41598-024-55755-6","volume":"14","author":"M Chantadisai","year":"2024","unstructured":"Chantadisai M, Wongwijitsook J, Ritlumlert N, Rakvongthai Y. Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients. Sci Rep. 2024;14:5001.","journal-title":"Sci Rep"},{"key":"1049_CR74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4103\/wjnm.WJNM_104_20","volume":"20","author":"D Lubin","year":"2021","unstructured":"Lubin D, Tsetse C, Khorasani M, Allahyari M, McGrath M. Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: a single-center experience. World J Nucl Med. 2021;20:253\u20139.","journal-title":"World J Nucl Med"},{"key":"1049_CR75","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1093\/oncolo\/oyad252","volume":"29","author":"R Sa","year":"2024","unstructured":"Sa R, Yang T, Zhang Z, Guan F. Random forest for predicting treatment response to radioiodine and thyrotropin suppression therapy in patients with differentiated thyroid cancer but without structural disease. Oncologist. 2024;29:e68-80.","journal-title":"Oncologist"},{"key":"1049_CR76","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14639\/0392-100X-N3029","volume":"44","author":"O B\u00fclb\u00fcl","year":"2024","unstructured":"B\u00fclb\u00fcl O, Nak D. Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning. Acta Otorhinolaryngol Ital. 2024;44:261\u20138.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"1049_CR77","doi-asserted-by":"publisher","first-page":"1425101","DOI":"10.3389\/fendo.2024.1425101","volume":"15","author":"JJ Liu","year":"2024","unstructured":"Liu JJ, Wang ZY, Yue YF, et al. A predictive model for L-T4 dose in postoperative DTC after RAI therapy and its clinical validation in two institutions. Front Endocrinol (Lausanne). 2024;15:1425101.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR78","doi-asserted-by":"publisher","first-page":"1415206","DOI":"10.3389\/fendo.2025.1415206","volume":"16","author":"TT Ngan","year":"2025","unstructured":"Ngan TT, Tra DH, Mai NTQ, et al. Developing a machine learning-based predictive model for levothyroxine dosage estimation in hypothyroid patients: a retrospective study. Front Endocrinol (Lausanne). 2025;16:1415206.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR79","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0119","volume":"11","author":"L Duan","year":"2022","unstructured":"Duan L, Zhang H, Lv M, et al. Machine learning identifies baseline clinical features that predict early hypothyroidism in patients with Graves\u2019 disease after radioiodine therapy. Endocr Connect. 2022;11:e220119.","journal-title":"Endocr Connect"},{"key":"1049_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/mp.70072","volume":"52","author":"C Wang","year":"2025","unstructured":"Wang C, Hu G, Ji F, et al. A multi-scale network for thyroid segmentation and dose assessment in hyperthyroid patients with uncertainty quantification. Med Phys. 2025;52:e70072.","journal-title":"Med Phys"},{"key":"1049_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12146-4","volume":"24","author":"H Wang","year":"2024","unstructured":"Wang H, Zhang C, Li Q, et al. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches. BMC Cancer. 2024;24:427.","journal-title":"BMC Cancer"},{"key":"1049_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027493","volume":"100","author":"SY Kim","year":"2021","unstructured":"Kim SY, Kim YI, Kim HJ, et al. New approach of prediction of recurrence in thyroid cancer patients using machine learning. Medicine (Baltimore). 2021;100:e27493.","journal-title":"Medicine (Baltimore)"},{"key":"1049_CR83","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/cancers15020550","volume":"15","author":"SW Jang","year":"2023","unstructured":"Jang SW, Park JH, Kim HR, et al. Recurrence risk evaluation in patients with papillary thyroid carcinoma: multicenter machine learning evaluation of lymph node variables. Cancers (Basel). 2023;15:550.","journal-title":"Cancers (Basel)"},{"key":"1049_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131684","volume":"15","author":"K Shrestha","year":"2025","unstructured":"Shrestha K, Rifat HMJO, Biswas U, Tiang JJ, Nahid AA. Predicting the recurrence of differentiated thyroid cancer using whale optimization-based XGBoost algorithm. Diagnostics (Basel). 2025;15:1684.","journal-title":"Diagnostics (Basel)"},{"key":"1049_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2025.101702","volume":"59","author":"MA Deif","year":"2025","unstructured":"Deif MA, Akour I, Elhoseny M. Optimizing thyroid cancer recurrence prediction using tribal intelligent evolution and XGBoost: toward enhanced clinical decision support. Inform Med Unlocked. 2025;59:101702.","journal-title":"Inform Med Unlocked"},{"key":"1049_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2025.101715","volume":"59","author":"A Triayudi","year":"2025","unstructured":"Triayudi A, Hisni D, Sari RTK. An adaptive multi-source fuzzy co-clustering and knowledge distillation framework for predicting thyroid cancer recurrence: toward interpretable and clinically deployable models. Inform Med Unlocked. 2025;59:101715.","journal-title":"Inform Med Unlocked"},{"key":"1049_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.651534","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Li Y, Teng D, et al. Hyperthyroidism prevalence in China after universal salt iodization. Front Endocrinol (Lausanne). 2021;12:651534.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1049_CR88","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8:227\u201345.","journal-title":"Eur Thyroid J"},{"key":"1049_CR89","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5603\/ep.100533","volume":"75","author":"A Ledwon","year":"2024","unstructured":"Ledwon A, Kropi\u0144ska A, Paliczka-Cie\u015blik E, et al. Recurrence patterns in differentiated thyroid cancer (DTC) following adjuvant radioiodine therapy. Endokrynol Pol. 2024;75:486\u201393.","journal-title":"Endokrynol Pol"},{"key":"1049_CR90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/ERC-10-0233","volume":"18","author":"D Deandreis","year":"2011","unstructured":"Deandreis D, Al Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159\u201369.","journal-title":"Endocr Relat Cancer"},{"key":"1049_CR91","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s12020-024-03943-9","volume":"86","author":"J Ma","year":"2024","unstructured":"Ma J, Leng Z, Zuo D, Zhang X, Zhang C, Chen H, et al. A novel nomogram to predict glucocorticoid response in thyroid-associated ophthalmopathy: findings from a pilot study. Endocrine. 2024;86:824\u201333.","journal-title":"Endocrine"},{"key":"1049_CR92","doi-asserted-by":"publisher","first-page":"1656919","DOI":"10.3389\/fonc.2025.1656919","volume":"15","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, Yu Y, Li J, Ma T, Liu W. Comparison of an AI-assisted system (S-detect) and sonographers of different experience levels in diagnosing thyroid nodules: a retrospective study. Front Oncol. 2025;15:1656919.","journal-title":"Front Oncol"},{"key":"1049_CR93","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/jmai-23-180","volume":"7","author":"S Vachatimanont","year":"2024","unstructured":"Vachatimanont S, Kingpetch K. Exploring the capabilities and limitations of large language models in nuclear medicine knowledge with primary focus on GPT-3.5, GPT-4 and Google Bard. Journal of Medical Artificial Intelligence. 2024;7:5.","journal-title":"Journal of Medical Artificial Intelligence"},{"key":"1049_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.","journal-title":"BMJ"},{"key":"1049_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KGM Moons","year":"2025","unstructured":"Moons KGM, Damen JAA, Kaul T, Hooft L, Andaur Navarro C, Dhiman P, et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505.","journal-title":"BMJ"},{"key":"1049_CR96","unstructured":"National Heart, Lung, and Blood Institute. Study Quality Assessment Tools. Bethesda (MD): National Institutes of Health; 2013. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"1049_CR97","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190001","volume":"92","author":"D Jarrett","year":"2019","unstructured":"Jarrett D, Stride E, Vallis K, Gooding MJ. Applications and limitations of machine learning in radiation oncology. Br J Radiol. 2019;92:20190001.","journal-title":"Br J Radiol"},{"key":"1049_CR98","doi-asserted-by":"publisher","DOI":"10.2196\/47609","volume":"25","author":"AA Nichol","year":"2023","unstructured":"Nichol AA, Sankar PL, Halley MC, Federico CA, Cho MK. Developer perspectives on potential harms of machine learning predictive analytics in health care: qualitative analysis. J Med Internet Res. 2023;25:e47609.","journal-title":"J Med Internet Res"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-026-01049-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:02:24Z","timestamp":1790762544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-026-01049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s13139-026-01049-w","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based exclusively on previously published literature and does not involve any new studies with human participants or animals performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors did not use generative AI in writing except for checking grammar, spelling, references..","order":4,"name":"Ethics","label":"Declaration of generative AI in scientific writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No preprint version of this manuscript has been posted or is under consideration elsewhere.","order":5,"name":"Ethics","label":"Preprint sharing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria Obrycka, Saeid Abdelrazek, \u0141ukasz \u017bukowski, Janusz My\u015bliwiec and Piotr Szumowski declare that they have no conflict of interest.","order":6,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}